with APE ( Fig. 2 ) in cases 1 and 2. In case 3, both episodes of active bleeding were able to be contained through APE. We found an association with autoimmune diseases and with immunosuppressant treatment, concurring with reports in the literature. 1, 4, 6 Treatment in adults for GAVE consists of endoscopic management with APE, laser photoablation, nitrous oxide cryotherapy, and coagulation with hemospray. APE is the most widely used technique due to its availability and its generally reversible complications, such as distension due to gas, emphysema, and gastrointestinal pneumatosis, unlike the complications of perforation or ulcers that can arise with other endoscopic techniques. 2, 5 Other reported treatments are antrectomy, which involves greater morbidity and mortality, and medical treatments with hormones, steroids, or tranexamic acid. The latter have not been efficacious, given that they require longterm management and cause adverse effects and relapse when suspended. Some reports state that acute bleeding has been controlled with octreotide. 2, 5, 6 There is little information on the use of APE in children for managing bleeding caused by GAVE. Our cases did not present with complications.
We can conclude that APE in children with GAVE, as in adults, is useful for controlling active bleeding, without causing serious complications. The pathology should be suspected in children presenting with gastrointestinal bleeding that causes anemia, who are undergoing treatment with immunosuppressants and/or have an autoimmune disease. Biopsy may not always report vascular lesions. An endoscopic image characteristic of GVE with no other etiology for gastrointestinal bleeding that responds favorably to APE treatment supports the diagnosis. GAVE should be considered a cause of gastrointestinal bleeding in the pediatric population.
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No financial support was received in relation to this study. Recurrent tracheoesophageal fistulas (TEFs) may present in 1.9 to 20% of cases after surgical primary closure in patients with esophageal atresia (EA) and TEF.
1 ---3 Respiratory symptoms of chronic cough, episodes of choking and/or cyanosis after eating, recurrent pneumonia, chronic lung disease, and malnutrition should lead to diagnostic suspicion. esophagogastroduodenoscopy (EGD) are the diagnostic methods of choice, but repeat studies may be required for confirmation. 5 Endoscopic treatment of recurrent TEF has been described as a therapeutic alternative to repeat open chest surgery repair. Some studies have reported on the use of tissue adhesives such as N-butyl-cyanoacrylate (Histoacryl ® ), fibrin or sclerosing agents, and laser. 1 ---3 We describe herein the case of a preschool child with recurrent TEF managed with a combination of Histoacryl ® and lipiodol via esophageal endoscopy.
5
A 3-year-old girl was delivered by cesarean section at 34 weeks of gestation, G2, weighing 1.5 kg, and measuring 40 cm. She had a past history of severe oligohydramnios, intrauterine growth retardation, and umbilical catheterization. She underwent esophagoplasty at 5 days of life with fistula closure due to type III EA and TEF at another institution. At 19 months of age the patient was referred to the Gastroenterology and Nutrition Service of our hospital because of upper gastrointestinal bleeding causing anemia. She was diagnosed with grade III esophageal varices secondary to portal hypertension and cavernous transformation of the portal vein and was managed with endoscopic variceal band ligation and sclerotherapy with no complications. Starting at 24 months of life, the patient presented with symptoms of repeat pneumonia, gastroesophageal reflux, bronchial hyperreactivity, esophageal candidiasis, pediatric chronic lung disease, and chronic malnutrition, meriting numerous hospitalizations and the use of proton pump inhibitors, inhaled steroids, and short-acting bronchodilators. An EGD was performed when the patient was 3 years old, identifying the TEF opening at 16 cm from the
